Galectin-3 Involvement in Cognitive Processes for New Therapeutic Considerations

Overview

Journal Front Cell Neurosci

Specialty Cell Biology

Date 2022 Jul 25

PMID 35875353

Authors

Natasa R Mijailovic

Katarina Vesic

Dragana Arsenijevic

Maja Milojevic-Rakic

Milica M Borovcanin

Affiliations

Soon will be listed here.

Abstract

Cognitive impairment may be a consequence of the normal aging process, but it may also be the hallmark of various neurodegenerative and psychiatric diseases. Early identification of individuals at particular risk for cognitive decline is critical, as it is imperative to maintain a cognitive reserve in these neuropsychiatric entities. In recent years, galectin-3 (Gal-3), a member of the galectin family, has received considerable attention with respect to aspects of neuroinflammation and neurodegeneration. The mechanisms behind the putative relationship between Gal-3 and cognitive impairment are not yet clear. Intrigued by this versatile molecule and its unique modular architecture, the latest data on this relationship are presented here. This mini-review summarizes recent findings on the mechanisms by which Gal-3 affects cognitive functioning in both animal and human models. Particular emphasis is placed on the role of Gal-3 in modulating the inflammatory response as a fine-tuner of microglia morphology and phenotype. A review of recent literature on the utility of Gal-3 as a biomarker is provided, and approaches to strategically exploit Gal-3 activities with therapeutic intentions in neuropsychiatric diseases are outlined.

Citing Articles

Development and validation of Galectin-3 and CVAI-based model for predicting cognitive impairment in type 2 diabetes.

Zhou X, Dai N, Yu D, Niu T, Wang S J Endocrinol Invest. 2024; .

PMID: 39565520 DOI: 10.1007/s40618-024-02506-z.

The known and unknown about attention deficit hyperactivity disorder (ADHD) genetics: a special emphasis on Arab population.

Mahrous N, Albaqami A, Saleem R, Khoja B, Khan M, Hawsawi Y Front Genet. 2024; 15:1405453.

PMID: 39165752 PMC: 11333229. DOI: 10.3389/fgene.2024.1405453.

Exploring galectin-3's role in predicting mild cognitive impairment in type 2 diabetes and its regulation by miRNAs.

Zhou X, Dai N, Yu D, Niu T, Wang S Front Med (Lausanne). 2024; 11:1443133.

PMID: 39144658 PMC: 11322075. DOI: 10.3389/fmed.2024.1443133.

Single cells and TRUST4 reveal immunological features of the HFRS transcriptome.

Xiao R, Lin M, Liu M, Ma Q Front Med (Lausanne). 2024; 11:1403335.

PMID: 38803345 PMC: 11128564. DOI: 10.3389/fmed.2024.1403335.

Multiple cancer cell types release LIF and Gal3 to hijack neural signals.

Xu Q, Cao Y, Kong F, Liu J, Chen X, Zhao Y Cell Res. 2024; 34(5):345-354.

PMID: 38467743 PMC: 11061112. DOI: 10.1038/s41422-024-00946-z.

References

James R, Hillis J, Adorjan I, Gration B, Mundim M, Iqbal A . Loss of galectin-3 decreases the number of immune cells in the subventricular zone and restores proliferation in a viral model of multiple sclerosis. Glia. 2015; 64(1):105-21. PMC: 4988318. DOI: 10.1002/glia.22906. View

Sierra A, Tremblay M, Wake H . Never-resting microglia: physiological roles in the healthy brain and pathological implications. Front Cell Neurosci. 2014; 8:240. PMC: 4133768. DOI: 10.3389/fncel.2014.00240. View

Nio-Kobayashi J, Itabashi T . Galectins and Their Ligand Glycoconjugates in the Central Nervous System Under Physiological and Pathological Conditions. Front Neuroanat. 2021; 15:767330. PMC: 8554236. DOI: 10.3389/fnana.2021.767330. View

Rahimian R, Beland L, Sato S, Kriz J . Microglia-derived galectin-3 in neuroinflammation; a bittersweet ligand?. Med Res Rev. 2021; 41(4):2582-2589. DOI: 10.1002/med.21784. View

Sole B, Jimenez E, Torrent C, Reinares M, Bonnin C, Torres I . Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies. Int J Neuropsychopharmacol. 2017; 20(8):670-680. PMC: 5570032. DOI: 10.1093/ijnp/pyx032. View

Soares L, Al-Dalahmah O, Hillis J, Young C, Asbed I, Sakaguchi M . Novel Galectin-3 Roles in Neurogenesis, Inflammation and Neurological Diseases. Cells. 2021; 10(11). PMC: 8618878. DOI: 10.3390/cells10113047. View

Hanke M, Kielian T . Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin Sci (Lond). 2011; 121(9):367-87. PMC: 4231819. DOI: 10.1042/CS20110164. View

Boza-Serrano A, Reyes J, Rey N, Leffler H, Bousset L, Nilsson U . The role of Galectin-3 in α-synuclein-induced microglial activation. Acta Neuropathol Commun. 2014; 2:156. PMC: 4236422. DOI: 10.1186/s40478-014-0156-0. View

Gu Y, Vorburger R, Scarmeas N, Luchsinger J, Manly J, Schupf N . Circulating inflammatory biomarkers in relation to brain structural measurements in a non-demented elderly population. Brain Behav Immun. 2017; 65:150-160. PMC: 5537030. DOI: 10.1016/j.bbi.2017.04.022. View

10.

Boitard C, Cavaroc A, Sauvant J, Aubert A, Castanon N, Laye S . Impairment of hippocampal-dependent memory induced by juvenile high-fat diet intake is associated with enhanced hippocampal inflammation in rats. Brain Behav Immun. 2014; 40:9-17. DOI: 10.1016/j.bbi.2014.03.005. View

11.

Nickel W . The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. Eur J Biochem. 2003; 270(10):2109-19. DOI: 10.1046/j.1432-1033.2003.03577.x. View

12.

Ahnstedt H, Patrizz A, Chauhan A, Roy-OReilly M, Furr J, Spychala M . Sex differences in T cell immune responses, gut permeability and outcome after ischemic stroke in aged mice. Brain Behav Immun. 2020; 87:556-567. PMC: 7590503. DOI: 10.1016/j.bbi.2020.02.001. View

13.

Shin T . The pleiotropic effects of galectin-3 in neuroinflammation: a review. Acta Histochem. 2013; 115(5):407-11. DOI: 10.1016/j.acthis.2012.11.010. View

14.

Yan X, Yu G, Jie Y, Fan X, Huang Q, Dai W . Role of galectin-3 in plasma as a predictive biomarker of outcome after acute intracerebral hemorrhage. J Neurol Sci. 2016; 368:121-7. DOI: 10.1016/j.jns.2016.06.071. View

15.

Yoo H, Kim E, Lee E, Hong S, Yoon C, Hong M . Neuroanatomical distribution of galectin-3 in the adult rat brain. J Mol Histol. 2017; 48(2):133-146. DOI: 10.1007/s10735-017-9712-9. View

16.

Melo F, Butera D, de Souza Junqueira M, Hsu D, Moura da Silva A, Liu F . The promigratory activity of the matricellular protein galectin-3 depends on the activation of PI-3 kinase. PLoS One. 2012; 6(12):e29313. PMC: 3247242. DOI: 10.1371/journal.pone.0029313. View

17.

Mishra A, Bandopadhyay R, Singh P, Mishra P, Sharma N, Khurana N . Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside. Metab Brain Dis. 2021; 36(7):1591-1626. DOI: 10.1007/s11011-021-00806-4. View

18.

Chen P, Cheng S, Lin H, Lee C, Chou C . Risk Factors for the Progression of Mild Cognitive Impairment in Different Types of Neurodegenerative Disorders. Behav Neurol. 2018; 2018:6929732. PMC: 6008817. DOI: 10.1155/2018/6929732. View

19.

Chan Y, Lin H, Tu Z, Kuo Y, Hsu S, Lin C . Dissecting the Structure-Activity Relationship of Galectin-Ligand Interactions. Int J Mol Sci. 2018; 19(2). PMC: 5855614. DOI: 10.3390/ijms19020392. View

20.

Christensen B, Colella B, Inness E, Hebert D, Monette G, Bayley M . Recovery of cognitive function after traumatic brain injury: a multilevel modeling analysis of Canadian outcomes. Arch Phys Med Rehabil. 2008; 89(12 Suppl):S3-15. DOI: 10.1016/j.apmr.2008.10.002. View